Intuitive Surgical: When a Beat Becomes a Sell-Off, and Analysts Push Back

Intuitive Surgical beat Q2 estimates but cut 2026 procedure growth forecast, sparking an 11% sell-off. UBS and Bernstein see upside, citing automation and long-term growth drivers.

The numbers were good. The stock tanked anyway. That was the story for Intuitive Surgical earlier this month, when second-quarter results that topped every major metric were overshadowed by a sobering cut to the company's procedure-growth forecast. The ensuing 11% drop has since given way to a partial recovery, but the debate over whether the sell-off was justified — or an overreaction to temporary headwinds — is far from settled.

Revenue for the quarter came in at $2.89 billion, up 18.4% year over year and ahead of the $2.81 billion consensus. Adjusted earnings per share of $2.80 handily beat expectations of roughly $2.50, marking the fifth straight quarter of upside surprises. The company also raised its full-year gross margin guidance to a range of 68% to 69%, from a prior 67.5% to 68.5%. On paper, the quarter looked like a win.

The trouble came with the forward view. Management lowered its 2026 da Vinci procedure growth forecast to a range of 13.5% to 15.5%, down from the 18% it had projected for 2025. U.S. procedure growth slowed to 12% in the second quarter, weighed down by several factors: the impact of ACA premium dynamics on the U.S. healthcare system, the ripple effects of GLP-1 weight-loss drugs on bariatric surgeries — a key robotic surgery segment — and weakness in China. International procedure growth, by contrast, ran at 20%. Of the 468 systems shipped in the quarter, 246 were the new da Vinci 5 generation, and U.S. system placements rose 24%.

The market reaction was swift and severe. The stock lost roughly 11% in the session following the report, though it has since clawed back some ground. On a weekly basis, the shares are up about 6.38%, closing Tuesday at €320.45, a gain of 2.22% on the day. Still, the year-to-date picture is grim: the stock is down roughly 35%, and it remains 38.5% below its 52-week high of €516.50.

UBS and Bernstein See Opportunity in the Wreckage

Into that uncertainty stepped UBS, which initiated coverage of Intuitive Surgical on Tuesday with a Buy rating and a price target of $500 — reduced from a previously reported $550, but still well above the current level. The bank's analysts argue that the recent sell-off was overdone and that automation, not near-term procedure counts, is the real story. They expect the company to deliver annual revenue growth of roughly 15% over the next five years, driven by heart surgery, endoluminal procedures, and the ION platform. The automation potential, they say, is an underappreciated value driver.

Bernstein is even more bullish, maintaining an Outperform rating with a $685 target, albeit down from an earlier $750. The average analyst price target sits at $484.40, suggesting meaningful upside from current levels. Most analysts still recommend buying the stock, though the range of opinions is wide.

The UBS upgrade came just days after the company's "Intuitive 360 Korea" event in Seoul on July 25, where it positioned its systems not merely as surgical tools but as part of a broader, data-driven platform encompassing training and consulting. The "total solution" strategy is designed to embed the company deeper into hospital workflows, making its revenue stream less dependent on the lumpiness of hardware sales.

A Balance Sheet That Can Weather the Storm

Despite the growth concerns, the financial foundation remains solid. Intuitive Surgical holds $8.6 billion in cash. In the second quarter, it bought back $379 million worth of its own shares at an average price of $439 — well above the current trading level. Insider sales during the period were modest, totaling roughly $3.1 million.

The technical picture, however, underscores the uncertainty. The stock remains 23.18% below its 200-day moving average of €417.12. The relative strength index sits at 44.1, suggesting the stock has stabilized after being oversold but hasn't yet built momentum. The 30-day annualized volatility of 57.64% signals that large swings are likely to continue.

For investors, the question boils down to whether the U.S. slowdown in elective procedures is a temporary blip or a longer-term drag. The bull case, championed by UBS and Bernstein, rests on the structural shift toward automation in hospitals and the eventual adoption of the da Vinci 5. The bear case points to the GLP-1 effect, China headwinds, and a cautious U.S. procedure environment. Both sides are betting on the same underlying question: will robotic surgery become a necessity for modern hospitals, or will it remain a cost center that gets deferred when budgets tighten?

The analyst consensus leans toward the optimistic view, with a mean price target of €425.89, implying roughly 33% upside. Whether that target is reached depends on how quickly the da Vinci 5 gains traction — and whether U.S. hospitals shake off their current reluctance to schedule non-urgent surgeries.